Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Kyle

Showing results (861-870 of 874) with videos related to

Pageof 88
Sort By:
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
British Journal of Haematology|March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerationsLaura Rosiñol, Meral Beksac, Elena Zamagni, et al.
Leukemia|January 5, 2013
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupC Fernández de Larrea, R A Kyle, B G M Durie, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
Journal of the American College of Radiology : JACR|February 6, 2026
Recommendations From the Blue Ribbon Panel on Fluoroscopy SafetyDustin A Gress, M Mahesh, Kevin W Dickey, et al.
Pageof 88

Showing results (861-870 of 874) with videos related to

Sort By:
Pageof 88
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
British Journal of Haematology|March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerationsLaura Rosiñol, Meral Beksac, Elena Zamagni, et al.
Leukemia|January 5, 2013
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupC Fernández de Larrea, R A Kyle, B G M Durie, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
Journal of the American College of Radiology : JACR|February 6, 2026
Recommendations From the Blue Ribbon Panel on Fluoroscopy SafetyDustin A Gress, M Mahesh, Kevin W Dickey, et al.
Pageof 88